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ABSTRACT
The major transmission route for hepatitis C virus (HCV) is sharing of unsterile 
injection equipment (needle/syringes and paraphernalia). Needle exchange pro-
grams (NEP) reduce injection risk behaviour and HCV spread among people who 
inject drugs (PWID). WHO has set a goal to eliminate HCV by the year 2030. To 
achieve this, a better understanding of the HCV spread among PWID is needed. 
The aims of this thesis were to study the HCV prevalence, incidence, spontaneous 
clearance, level of liver fibrosis and change in injection risk behaviour in PWID 
in the NEP in Stockholm.
In Study I (n=1386), we found a high 60% baseline prevalence of HCV infec-
tion in PWID and that participants became HCV infected at an early stage. Thus, 
50% became anti-HCV positive within 2-5 years after start of injection drug use 
(IDU). Furthermore, the participants had a low awareness of their HCV status. This 
will have influence on injection risk behaviour and will increase the risk of HCV 
transmission. These findings indicate that prevention and harm reduction measures 
need to be implemented early on. In Study II, we investigated the HCV incidence 
among NEP participants (n=584). Overall, a high incidence rate corresponding to 
22/100 person-years was noted. Factors associated with becoming HCV infected 
were female gender, homelessness and amphetamine use. Spontaneously clear-
ance among those with previous exposure of HCV was significantly higher than 
in those who were HCV naive. High coverage of NEP, scale-up of HCV treat-
ment and participation in effective treatment for substance use disorders, such as 
opioid substitution treatment (OST) need to be implemented to reduce the HCV 
transmission. In Study III, we investigated the level of HCV related liver fibrosis 
with liver stiffness measurement (LSM) among participants (n=203) and found 
that 15% had advanced fibrosis in need of early treatment and HCC surveillance. 
We found that an age ≥ 40 years and duration of IDU ≥ 15 years in combination 
with an APRI score > 1, identified most participants with advanced fibrosis. This 
indicates that diagnostic work-up to detect advanced fibrosis can be simplified. 
In Study IV, we noted an overall significant reduction in injection risk behaviour 
of most baseline risk factors over time among participants (n=2860) in the NEP. 
Female gender, homelessness and amphetamine use were baseline determinants 
that correlated to an increased risk of sharing needle/syringes and paraphernalia, 
whereas OST was a protective factor.
To conclude, our studies have contributed to an increased knowledge about the 
prevalence and incidence of HCV infections in PWID, which highlights the need 
to enforce effective harm reduction interventions to prevent the spread of HCV. To 
eliminate HCV by the year 2030, as proposed by WHO, further implementation 
of NEP together with a scale-up of HCV treatment among PWID and easy access 
to treatment for all participants is needed. 
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11 INTRODUCTION
An estimated 71 million people worldwide are infected with hepatitis C virus 
(HCV) [1]. Among people who inject drugs (PWID) the prevalence of HCV is 
high, and the major route for HCV transmission is sharing of unsterile injection 
equipment (needle/syringes and other drug paraphernalia) [2, 3]. Among the 15.6 
million people with recent injection drug use (IDU) worldwide, 6.1 million (39%) 
are estimated to be HCV infected. The global burden of disease related to previous 
exposure to HIV, hepatitis B (HBV), and HCV via IDU accounts for more than 10 
million disability-adjusted life years (DALYs). Furthermore, it is estimated that 7 
million DALYs are caused by the long-term adverse events caused by HCV [4]. 
Needle exchange programs (NEP), also called needle syringe programs (NSP), 
significantly impact both risk behaviour and HIV and HCV spread in PWID [5-8]. 
In 2016, the World Health Organization (WHO) presented goals for eliminating 
HBV and HCV by year 2030, and the scale-up of harm reduction programs [9]. 
Several focus-areas were proposed, including thorough investigation of the effi-
cacy of prevention programs. Testing for blood-borne viruses (BBVs), diagnosis, 
linkage to care and prevention of reinfections all need to be increased to reach 
the elimination goal [10]. 
HCV treatment with direct acting antivirals (DAAs) achieve cure rates > 95% [10]. 
The WHO targets for HCV elimination by 2030, include a 90% reduction of new 
HCV cases, 80% treated HCV cases and a 65% reduction of HCV related deaths 
[11]. With the increased availability of DAA treatment in Europe and in the world, 
the feasibility of HCV elimination as proposed by the WHO will increase [12]. 
Previous meta-analyses have concluded that there is evidence that NEP reduce 
injection risk behaviour and transmission of HIV, but insufficient data concerning 
the effectiveness for prevention of HCV transmission [13, 14]. Other studies, how-
ever, have highlighted the effectiveness of NEP in particular when combining NEP 
with opioid substitution treatment (OST) to prevent HCV transmission [6, 13, 15]. 
In 2017, an article sanctioned by the International Network on Hepatitis in Substance 
Users (INHSU), highlighted research priorities needed to achieve universal access 
to hepatitis C prevention, management and DAA treatment in PWID. Among a 
total of 38 prioritised bullet points, the following were addressed [16]:
• Updated national and regional estimates of the prevalence and numbers of 
PWID and characteristics of these populations
• Updated national and regional estimates of the incidence, prevalence and 
number of people with HCV infection in PWID and opiate substitution 
treatment (OST) populations
2• Evaluation of the implementation effectiveness, and scale-up of existing 
HCV-prevention interventions for PWID including OST, needle exchange 
programs, and treatment as prevention
• Evaluation of DAA treatment access and treatment reimbursement restric-
tions (e.g. fibrosis stages, drug/alcohol use and prescriber type)
• Evaluation of treatment efficacy in PWID and the long-term rate of HCV 
reinfections following a successful HCV treatment in PWID
The above listed priorities represent parts of the aims for this thesis. In our studies 
we investigated HCV prevalence, incidence, spontaneous clearance and change 
in injection risk behaviour in PWID over time in the NEP in Stockholm, Sweden. 
Furthermore, we investigated HCV related liver fibrosis and APRI score and 
demographic determinants, such as age and duration of IDU, to differentiate mild 
versus advanced fibrosis. All our data and results are discussed in the context of 
general HCV prevention and also in the light of the present WHO guided HCV 
elimination strategy.
32 HEPATITIS C
2.1 The hepatitis C virus
The hepatitis C virus is an enveloped single stranded RNA virus of the genus 
Hepacivirus within the Flaviviridae family. It was discovered in 1989, although its 
existence was observed and described already in 1975, as a ‘transfusion-associated 
hepatitis’ and later as non-A, non-B hepatitis [17, 18]. 
HCV is transmitted when HCV infected blood comes in contact with another indi-
vidual’s blood stream. The major HCV transmission route in the Western world 
is the sharing of unsterile injection equipment among PWID [1, 3, 19]. Injection 
equipment include needle and syringes as well as other drug paraphernalia (cook-
ers/filters/water). HCV may also be transmitted among people who use drugs 
(PWUD), who do not inject drugs, through the sharing of snorting and smoking 
paraphernalia (e.g. snort tubes and crack pipes) [20-22], although some studies 
have not found this association [23, 24]. HCV may contain infectivity days to 
weeks outside the body, which adds to the risk of transmission [25, 26]. 
Historically, and still present in some low resource settings, HCV may have an 
iatrogenic spread due to poor hygienic practices and the lack of testing for HCV in 
conjunction with blood transfusion, blood products, invasive procedures and vac-
cinations [27, 28]. This may also include tattooing and piercing practices [29, 30]. 
Sexually transmitted HCV among heterosexual partners is rare [31-33]. However, 
among men who have sex with men (MSM), the HCV transmission risk is increased 
through high-risk traumatic sexual practices and also through mucosally admin-
istred recreational drugs and sexualized drug use, also called ‘chemsex’ [34, 35].
The risk of perinatal (mother to child) transmission of HCV is around 4-5% [36, 37].
2.2 Natural history
HCV infects the liver cells and cause a chronic HCV infection in about 60-80% of 
cases. Conversely, 20-40% spontaneously clear the infection, the majority within six 
months (fig. 1). A prospective HCV study noted that the median time for spontane-
ous clearance was 16.5 weeks, and that 34%, 67% and 83% of infected individuals 
cleared HCV within 3, 6 and 12 months, respectively [38]. Spontaneous clearance 
is associated with female gender, symptomatic acute infection and several genetic 
factors, including IL28B [38-42].
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Figure 1. Natural history of HCV infection [28].
Untreated chronic HCV infection could lead to severe liver fibrosis, liver cirrhosis, 
decompensated liver cirrhosis, hepatocellular carcinoma (HCC) and death [43]. 
Development of liver fibrosis evolves slowly and gradually but may be enhanced 
by multiple factors (e.g. alcohol use, HIV- or HBV co-infection, diabetes mellitus, 
gender, age and immunosuppression) [28, 44]. After 20-30 years, 10-20% develop 
cirrhosis, and cirrhosis progression seems to be accelerated with duration of time 
[28]. Once cirrhosis is established, HCC develops at a rate between 1% and 5% 
per year [28, 45, 46].
2.3 Prevalence and genotypes
In 2015, the global prevalence of HCV infection was estimated to be 1.0% cor-
responding to 71 million people living with HCV [1].
52.3.1 Prevalence in Sweden 
The overall prevalence of HCV in Sweden is estimated to be < 0.5% [43]. Since 
1990, notification of acute and chronic HCV is mandatory to the Public Health 
Agency of Sweden, previously the Swedish Institute for Infectious Disease Control. 
Between 1990-2015, a total of 64,200 cases of HCV were reported to the Swedish 
National Surveillance Register [47]. Taking into account the diseased, emigrated, 
reported missing, successfully treated and spontaneously cleared cases, the Public 
Health Agency of Sweden estimated a total of 35,000 to 45,000 people living with 
HCV in Sweden in 2016. However, in this estimate, the number of undiagnosed 
HCV infections was not accounted for. The updated estimate for 2018 is 25,000-
35,000 [48]. In previous Swedish estimates, the proportion of undiagnosed HCV 
cases was set to be around 20%, thus leaving an estimated number of 30,000 to 
42,000 people living with HCV in Sweden in 2018 [49-51]. 
Annually, about 2,000 new HCV cases are reported in Sweden. Of these, approxi-
mately 150 are considered to be newly infected, i.e. have an acute symptomatic 
HCV infection. During the last ten years, a slight downward trend has been seen 
in the number of cases and in 2018 just over 1,600 cases were reported [52, 53].
The median age for HCV diagnosis is around 35 years, which indicates late detec-
tion of disease within the group [54]. HCV transmission in Sweden is strongly 
linked to IDU and accounts for about 70% of all cases. A large proportion of other 
cases reported with an ‘unknown’ or ‘no information’ transmission route is reported 
from psychiatric and dependency disorder clinics or correctional services, which 
may indicate an underlying drug use [53]. In 2016, the Public Health Agency of 
Sweden reported that the number of IDU related HCV infections has decreased 
in recent years. A downward trend was mainly seen among teenagers and young 
adults. However, the group aged 15–24 still stands for a relatively high propor-
tion of all cases infected via IDU (20%) which indicates ongoing transmission of 
HCV among young people [53].
2.3.2 Genotypes and genotype distribution
HCV is classified in 7 major genotypes with a large number of underlying sub-
types [55]. 
On a global level, the dominating genotypes are genotype 1 (44%), genotype 
3 (25%) and genotype 4 (15%). Genotype 1 is more prevalent in high-income 
and upper-middle income countries (60%), genotype 3 in lower middle-income 
countries (36%) and genotype 4 in low-income countries (45%) [1]. There is a 
lower prevalence of genotype 1b and higher prevalence of genotype 1a and 3 in 
PWID globally, compared to the general population [56]. In Sweden, genotype 1 
and genotype 3 accounts for around 50% and 30% of cases, respectively and the 
corresponding figure among Swedish PWID is 36-54% and 33-40% [49, 57-59].
62.4 Diagnosis and treatment
HCV is diagnosed through virological testing. Serology detects specific anti-
bodies to HCV (anti-HCV) which are present life-long after infection, provides 
no immunity and indicates exposure to HCV (but not per se a viremic infection). 
Seroconversion appears on an average 6-8 weeks after exposure [60]. Another 
serological method to diagnose HCV is detection of HCV core antigen (HCV Ag) 
where a positive test confirms a viremic HCV infection. 
The gold standard for diagnosing a viremic HCV infection is detection of HCV 
RNA through PCR. HCV RNA is detectable as early as 1 week after exposure 
and at least 4-6 weeks before seroconversion [60]. As HCV may be spontaneously 
cleared, two consecutive positive HCV RNA tests (with 6 months in between) 
normally define a chronic HCV infection. The absence of HCV RNA at end of 
treatment (EOT) defines treatment effect and outcome and a negative HCV RNA 
test twelve weeks after EOT defines a successful HCV treatment and cure, called 
sustained virologic response (SVR).
2.4.1 Evolution of fibrosis evaluation
Evaluation of HCV related fibrosis pre-treatment is of great importance since it 
defines the level of fibrosis and thus defines the level of further pre- and post-
treatment investigations and follow-ups needed. Fibrosis stages may be classified 
in different ways but most often relate to fibrosis stages F0-F4, where F0-F1 rep-
resent absent or mild fibrosis, F2 significant fibrosis, F3 severe fibrosis and F4 
cirrhosis. In settings where universal access to HCV treatment still is restricted 
by level of fibrosis, evaluation of fibrosis pre-treatment may be a prerequisite to 
meet levels of defined treatment indications (e.g. fibrosis stage ≥F2) [12, 61, 62]. 
The gold standard of fibrosis evaluation is liver biopsy but given the definition 
of gold standard, as the ‘best available method under reasonable conditions’ [63], 
the noninvasive diagnostic methods of liver stiffness measurement (LSM) has 
challenged this. However, LSM is not necessarily easily available in all settings. 
2.4.2 Liver stiffness measurement (LSM)
LSM is performed with transient elastography, a non-invasive assessment of liver 
fibrosis [64, 65]. The method mostly used in Sweden is by FibroScan® and the 
result is obtained in kilo Pascal (kPa) where measured values are correlated to the 
stage of liver fibrosis (Metavir F0-F4) [66]. Liver stiffness cut-offs, used in the 
Swedish HCV treatment guidelines, are < 7 kPa for Metavir F0-F1, 7-9.4 kPa for 
Metavir F2, 9.5-12.4 kPa for Metavir F3 and ≥ 12.5 kPa for Metavir F4 indicating 
cirrhosis (fig. 2) [43, 67].
775 kPa
Absent or mild
fibrosis
(Metavir F0-F1) 
Significant
fibrosis
(F2)
2.5 7.0 9.5 12.5
Severe
fibrosis
(F3)
Cirrhosis
(F4)
Figure 2. Cut-offs in kPa corresponding to Metavir F0-F4 for liver stiffness measure-
ment (using FibroScan®) [67].
2.4.3 Fibrosis scores
There is a wide range of non-invasive tests to evaluate fibrosis, thus many differ-
ent blood tests and algorithms have been suggested as alternatives to liver biopsy 
and LSM. The overall conclusion in a review was that many tests are moderately 
useful and more reliable when identifying clinically significant fibrosis [68]. APRI 
(AST to platelet ratio index) score and FIB-4 (Fibrosis-4) score, used in this thesis 
(paper III), were considered to have a high and moderate strength of evidence for 
use, respectively, in the review [68].
2.4.4 Point-of-care testing
In recent years more easily accessible tests procedures have been developed to 
simplify screening and diagnosis. These tests do not necessarily need advanced 
laboratories to diagnose HCV and testing will thus be facilitated outside hospital 
and health care settings. A further advantage is that testing is possible through 
saliva or capillary blood, without venipuncture, which is of great benefit for the 
PWID population due to potential difficulties in finding a usable vein for blood 
sampling [69, 70]. Examples of point-of-care tests are rapid tests from saliva or 
blood (on-site anti-HCV and/or HCV RNA test) or dried blood-spot (anti-HCV 
and HCV RNA test, which still need further laboratory diagnostics) [71, 72].
2.4.5 Evolution of HCV treatment
Since the first introduction of HCV treatment, the cure rates have increased dra-
matically from around 6-7% in the early 1990s to an almost 100% cure rate since 
2015. In 1991 alfa interferon (INF) was approved as the first HCV treatment regime. 
8In 1998 ribavirin (RBV) was introduced as a compliment to INF-alfa. RBV is a 
synthetic nucleoside analogue with a broad antiviral spectrum and was initially 
developed to target HIV infection. Ribavirin was no success for treatment of HIV 
but when combined with INF, a synergistic effect increased the sustained virologic 
response (SVR) rates during treatment of HCV to around 34-42% and was a break-
through in HCV treatment [73, 74]. In 2002 when a modified, pegylated (PEG) 
interferon was introduced, treatment was not only simplified with a long-acting 
INF, but SVR was also overall increased to around 39% (without RBV) and 55% 
(with RBV). SVR for PEG-INF and RBV is dependent on genotypes, where cure 
rates for genotype 1 and 4 is 50% and for genotypes 2 and 3 80% [75].
The discovery and characterization of HCV encoded proteins and their functional 
units (i.e. NS3 protease, NS5A and the NS5B polymerase) was groundbreaking 
for the development of the direct acting antivirals (DAAs) [55]. When the first 
generation of DAAs was introduced, with the protease inhibitors (PI) telaprevir or 
boceprevir added to PEG-INF/RBV in genotypes 1 and 4, SVR rates increased to 
around 75% [76]. However, with this treatment strategy the rates of side-effects 
also increased with discontinuation rates of up to 40% [28]. 
With the second generation DAAs, introduced since 2014, SVR rates have gradu-
ally increased to >95% in most populations [77-81]. Treatment courses have been 
shortened to 8-12 weeks and the level of side-effects diminished, in comparison 
to the PEG-INF/RBV era [82, 83].
Accessed  
(year) 
NS5B 
polymerase 
inhibitor 
NS5A inhibitor NS3/4A protease 
inhibitor 
Genotype 
coverage 
2014 sofosbuvir 
  
1-6 
2014 
  
simeprevir 1+4 
2014  daclatasvir 
 
1-4 
2014 sofosbuvir ledipasvir 
 
1+4 
2015 
 
ombitasvir paritaprevir/ritonavir 1+4 
2015 dasabuvir 
  
1 
2016 sofosbuvir velpatasvir 
 
1-6 
2016 
 
elbasvir grazoprevir 1+4 
2017 
 
pibrentasvir glecaprevir 1-6 
2017 sofosbuvir velpatasvir voxilaprevir 1-6 
Figure 3. DAAs introduced since 2014. Current recommended/reimbursed drugs by 
The Swedish Association of Local Authorities and Regions, as per 2018-2019, are high-
lighted in grey [84].
92.4.6 Follow-up after treatment
Successful treatment, achieving SVR, is associated with a reduction in the risk 
for advanced fibrosis, decompensated liver cirrhosis, and HCC [85-88]. However, 
among those with advanced fibrosis, the risk for decompensation and HCC still 
remains after SVR [89, 90]. Risk factors associated with persistent advanced 
fibrosis and risk for HCC, are pre-treatment cirrhosis, high age, diabetes, and 
high BMI [91, 92]. Thus, there is a need for continuous follow-up of those with 
advanced fibrosis to screen for possible liver disease progression, and to address 
the associated life-style factors post SVR [91]. Current guidelines recommend 
post-treatment surveillance for HCC every 6 months [83]. 
Another indication for long-time follow-up after SVR, is the surveillance for 
possible reinfections among populations with continuous risk behaviours, mainly 
PWID and MSM. Here, repeated HCV testing is essential to minimise further 
transmission and to identify those in need of re-treatment.
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3 HEPATITIS C IN PWID
3.1 Prevalence of PWID and HCV
Among the 15.6 million people with recent injection drug use worldwide, 6.1 mil-
lion (39%) are estimated to be HCV infected, which corresponds to 8.5% of all 
HCV infections globally [93]. The global prevalence of PWID and viremic HCV 
prevalence among PWID, is shown in figure 4 and 5.
No evidence of IDU
IDU evidence, no estimate
>0·00% to <0·25%
≥0·25% to <0·50%
≥0·50% to <1%
≥1·00%
Figure 4. Global prevalence of PWID [94].
Figure 5. Global viremic HCV prevalence among PWID [93]. 
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A global overview of HCV prevalence and sociodemographic characteristics 
among PWID noted that PWID in general were more exposed to high risk envi-
ronments than the general population. PWID were at greater risk of police arrest, 
incarceration, sex work, and homelessness/unstable housing, which all are risk 
factors associated with increased HIV and hepatitis transmission [94].
3.2 Defining the PWID population
The definition of PWID has varied in the literature. Hence, for the evaluation of 
the prevalence, incidence and overall HCV treatment response among PWID, 
different definitions have been used. The PWID population may include those 
with previous injecting drug use (former PWID) and those with current injecting 
drug use (current PWID), most often varying from within the past 1-12 months. 
Sometimes even the entire OST population is defined as PWID, including those 
who are not currently injecting [10]. However, as shown in figure 6, there is often 
an overlap between these different categories, i.e. PWID in OST and current PWID.
Figure 6. Defining the PWID population and the possible overlap of other populations. 
Figure modified from Grebely et al. [10]. 
There are no defined criteria used for estimation of the number of PWID in Sweden. 
Historically, the term “severe drug use”, indicating use of illicit drugs on a daily 
basis or injection drug use at any occasion during the past twelve months, has been 
used. Among ‘severe drug users’ it is estimated that 90% are injecting drugs [95]. 
In 2015, the Public Health Agency of Sweden estimated the prevalence of PWID 
in Sweden during 2008-2012 to a total number of 8,021 (range 6,601-10,543) [54]. 
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This number was a dramatic decrease from the previous estimation of 26,500 
PWID [95]. In 2015, a Delphi process was used to gain country expert consensus 
in which the number of PWID in Sweden was estimated to approximately 21,000 
(Kåberg M, et al., unpublished).
3.3 Incidence of HCV in PWID
The incidence of HCV in PWID outside HCV treatment settings ranges from 
5-40% per year, with a median incidence rate (IR) of 26 new infections per 100 
person-years (26/100 PY) [2, 35, 96, 97]. Data from the NEP in Malmö, Sweden, 
investigating HCV incidence noted an incidence rate of 38/100 PY (adjusted 
32/100 PY) [98]. Known factors associated with HCV infection are younger age 
(<20 years), younger age at IDU debut (<17 years), sharing injection equipment, 
history of incarceration and the combined use of heroin and amphetamine [3, 96, 
98]. In a recent study from Spain the HCV incidence among new (IDU duration 
≤5 years) and long-term injectors was studied [99]. An increased IR of 25/100 PY 
among new injectors was found indicating that that HCV infection occur early 
after IDU debut, confirming previous findings [57, 100, 101].
In a Canadian population-based cohort study investigating the HCV incidence 
between 1990-2013, a total of 5915 individuals with a prior non-viremic HCV 
infection (3,690 with spontaneous cleared infection and 2,225 cleared after treat-
ment) were included. The overall proportion of reinfections was 11% (n=402) 
in the spontaneously cleared cohort, and 2% (n=50) in the successfully treated 
cohort. The overall IR was 1.3/100 PY with a follow-up time of 35,672 PY, and 
1.6/100 PY and 0.5/100 PY in the spontaneously cleared and successfully treated 
cohort, respectively [102]. Spontaneous clearance, HIV co-infection, and IDU 
were significantly associated with a higher risk of HCV reinfection and OST was 
significantly associated with a lower risk of reinfection [102]. 
In the era of WHO guided HCV elimination, concerns regarding reinfections 
among PWID have been raised by some policy makers and clinicians [10]. With 
a scale-up of HCV treatment in PWID, reinfections will occur due to on-going 
injection risk behaviour in this population. Previous studies on reinfection rates 
after successful INF-based treatment range from 2-6/100 PY but so far there are 
only a few studies on reinfection rates after the introduction of DAA treatment [35].
3.4 Injection risk behavior among PWID in Stockholm
In 2005, in the Stockholm pre-NEP era, Nordén et al. investigated injection risk 
behaviour among PWID [103]. Among the participants (n=46), 62% reported 
injection risk behaviour during the past year. No association between baseline 
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determinants (e.g. gender, living situation and injected drug) and sharing of 
 needle/syringes or paraphernalia was found, possibly explained by a low number 
of participants. In a study from 2009 (n=213), 71% of PWID participants reported 
sharing of needle/syringes the past six months and also a significantly increased 
level of concomitant sharing of paraphernalia [104]. 
In 2007-2008, a study was performed with the aim to investigate injection risk 
behaviour in active PWID in Stockholm (n=720). Among the participants, overall 
79% reported continuous risk behaviour of receptive sharing of needle/syringes, 
with women reporting a significantly higher risk behaviour compared to men 
[105, 106]. 
Self-reported sharing, and re-use of injection equipment among PWID in Stockholm, 
were also investigated in a pilot study in 2007, (n=30) [107]. The study concluded 
that injection equipment often was re-used and had a long turn-over time. Overall, 
the syringes had been used >5 times among 85% and >15 times among 46% of 
the participants. The corresponding figures for re-use of needles, with a shorter 
‘life span’, were 72% and 20%, respectively. Furthermore, all participants reported 
having shared needle/syringes or other paraphernalia at some time-point.
Among 2,150 remand prisoners in Stockholm, interviewed between 2002-2012, 66% 
reported having shared drug solution the past year and 62% and 56% acknowledged 
that they had received or lent out previously used needle/syringes, respectively. 
Factors associated with increased risk behaviour were female gender, homeless-
ness and amphetamine use [108].
3.5 Awareness of HCV 
An important factor for effective harm reduction among PWID is the awareness 
concerning whether you are infected and may transmit HCV or not. Awareness of 
HCV status is also essential for addressing HCV, enhancing the HCV care cascade 
and a prerequisite for HCV treatment. In Europe, the proportion of undiagnosed 
HCV infections in PWID range from 24% to 76% with a median of 49% [2]. 
The awareness of HCV status in Swedish PWID is not well studied, although one 
study from Stockholm has noted inadequate HCV awareness [104]. Other interna-
tional studies have also concluded that the concordance between the self-reported 
and actual anti-HCV status in PWID is poor [109-118]. So far, most  studies have 
examined awareness of anti-HCV status but not necessarily if a viremic and 
transmittable infection is at hand. However, one study utilizing HCV RNA test-
ing found an 80% concordance between self-reported HCV positive status and a 
positive HCV RNA test [113].
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Table 1. Studies investigating concordance between self-reported HCV status and 
HCV blood status among PWID. 
Table 1. Studies invesgang concordance between self-reported HCV status and  
HCV blood status among PWID.   
Study Country Parcipants Concordance with self-reported HCV status 
an-HCV- an-HCV+ An-HCV+/ An-HCV+/  Unknown  
HCV RNA+ HCV RNA- (but post-test 
 an-HCV+) 
  n n (%) n (%) n (%) n (%) n (%) 
Best D, et al UK 90 11/11 (100) 59/71 (83) - - 6/8 (75) 
1999 [118] 
Stein MD, et al USA 211 15/45 (33) 102/104 (98) - - 51/62 (82) 
2001 [117]  
Kwiatkowski CF, USA 197 - - - - 97/158 (61) 
 et al, 2002 [109] 
Schlicng EG, et al  USA 653 259/484 (54) 69/74 (93) - - - 
2003 [110] 
Hagan H, et al USA 3004 1062/1476 (72) 288/305 (94) - - 331/1223 (27) 
2006 [111] 
Day CA, et al Australia 208 20/37 (54) 142/146 (97) - - 8/13 (62) 
2008 [112] 
Nordén L, et al Sweden 212 13/16 (81) 131/134 (98) - - 33/62 (53) 
2009 [104] 
O’Keefe D, et al Australia 352 - - 123/152 (81) 97/122 (80)* 19/23 (83) 
2013 [113] 
Alanko Blomé M,  Sweden 229  96%** 69%** - - - 
et al, 2016 [116] 
Nielsen C, et al Germany 2030 339/716 (47) - 622/857 (73) 174/457 (38) - 
2016 [114] 
Iakunchykova O, Ukraine 1613 - 568/1002 (57) - - - 
et al, 2018 [115] 
* Figures represent self-reported answers ’negave’ and HCV blood status an-HCV- and an-HCV+/HCV-RNA-,  
** denominang numbers missing * Figures represent self-reported answers ’negative’ and HCV blood status anti-HCV- and 
anti-HCV+/HCV-RNA-, 
** denominating numbers missing
3.6 HCV related fibrosis
As previously discussed, untreated HCV may eventually progress to severe fibrosis, 
compensated liver cirrhosis, decompensated liver cirrhosis, hepatocellular carcinoma 
and death. To identify, to diagnose HCV and to initiate HCV treatment is therefore 
highly prioritized to prevent this development. 
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A review that examined HCV related liver fibrosis among PWID (21 studies) con-
cluded that if left untreated, the risk of severe complication will develop in mid- 
to late adulthood. The pooled fibrosis progression rate (FPR) was 0.12 Metavir 
units/year and the stage-specific FPRs were F0 to F1, 0.13; F1 to F2, 0.06; F2 to 
F3, 0.08; and F3 to F4, 0.12 Metavir units/year. The reported pooled incidence 
rates of compensated cirrhosis, decompensated cirrhosis, and HCC were 6.6, 1.8 
and 0.3 events per 1000 person-years, respectively. The average time to cirrhosis 
(F4) and F3 was 34 years and 26 years, respectively [119]. 
HCV related liver fibrosis was studied in a Norwegian long-term followed cohort 
of PWID. In autopsy material from 102 subjects, it was noted that 16% of HCV 
RNA positive subjects had fibrosis ≥F3, compared to only 2% among anti HCV 
positive/HCV RNA negative subjects. Furthermore, among PWID who had died 
<15 years after HCV exposure (n=18), none had fibrosis ≥F3 as compared to 35% 
(n=17) of those who had died >25 years after HCV exposure [120]. 
Another Norwegian study looked at all-cause mortality in a cohort of PWID and 
noted that HCV related liver mortality increased with age. The cumulative inci-
dence of liver related mortality among men was significantly higher in those >50 
years of age compared to those <50 years of age [121]. 
Other studies have also described increased HCV related liver morbidity in the OST 
population, explained by overall longer survival on OST and thus longer duration 
of the HCV infection [122]. In a Swedish study in OST participants, significant 
liver fibrosis was found in 67% of the HCV viremic participants (n=103), which 
was associated with alcohol intake, higher body mass index and the presence of 
anti-HBc antibodies [123]. Another Swedish study investigated ‘liver disease’ 
among subjects with opioid use disorder who participated in the Malmö NEP 
(n=1488). Liver related mortality was significantly higher among those who were 
ever prescribed OST, compared to those who were not, indicating longer survival 
and exposure to liver disease progression [124].
3.7 Liver stiffness measurement (LSM) in PWID
An Australian LSM assessment study (n=250) performed in 2015 concluded that 
there was a high LSM willingness and acceptability among PWID [125]. Prior 
to examination, 88% rated LSM as ‘very acceptable’, in comparison to 72% and 
32% for venipuncture and liver biopsy, respectively. After LSM, 95% rated it as 
‘very acceptable’ and the preferred method for liver fibrosis assessment (89%) 
compared to venipuncture (9%) and liver biopsy (2%) [125]. Participants further 
reported that they were ‘definitely willing’ to repeat an LSM in the future (91%) 
and to recommend LSM to their peers (93%) [125]. 
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Young PWID generally have mild fibrosis. Hence, in a DAA treatment study in 
a PWID/OST population with mean age of 48 years, 59% had no or mild fibrosis 
(F0-F1), 27% had moderate to advanced fibrosis and only 9% had cirrhosis when 
liver fibrosis was examined with LSM [126].
In an Indian study, in PWID (n=1,042), the overall anti-HCV and HCV RNA 
prevalence was 36% and 29%, respectively. Among HCV RNA positive partici-
pants 52%, 20% and 28% had no or mild, moderate and severe fibrosis/cirrhosis, 
respectively. Factors associated with severe fibrosis/cirrhosis were ‘persons who 
were older, had a longer duration of IDU, higher BMI, higher prevalence of insulin 
resistance, higher prevalence of steatosis, higher HCV RNA levels and evidence 
of alcohol dependence’ [127].
3.8 International and National HCV treatment guidelines 
concerning PWID
In international guidelines from the American Association for the Study of Liver 
Diseases (AASLD-IDSA), the European Association for the Study of the Liver 
(EASL) and INSHU, treatment of PWID is recommended as a prioritized task to 
reduce the risk of transmission [128-130]. However, in some settings in the US 
and Europe, DAA reimbursement restrictions are still in place for recent PWID 
[61, 131, 132].
In Swedish HCV treatment guidelines, on-going or recent drug use (including 
alcohol) was a relative contraindication for HCV treatment until 2015. In current 
recommendations these restrictions have been removed. In practice however, still 
few PWID are treated. Before 2018, HCV treatment was restricted to moderate or 
more advanced liver fibrosis and cirrhosis (F2-F4) [43]. At that time, the guide-
lines thus excluded the younger population (including many PWID) which in a 
majority only have mild fibrosis. 
There is evidence for acceptable HCV treatment adherence and high SVR rates 
within the OST population and among people with a history of IDU (including 
current/former IDU). SVR rates are thus comparable to those seen in people who 
do not inject drugs [129, 133, 134]. Despite this knowledge, HCV treatment uptake 
in PWID has previously been very low and limited to 1-2% of the population in 
studies from different countries [135-137].
Treatment uptake of HCV in active PWID has so far been low in Sweden and 
treatment in the OST-population also limited. The overall lifetime uptake of HCV 
treatment among PWID on OST has been between 1-6% in Sweden, but there are 
yet no published data on the yearly HCV treatment uptake among OST patients 
[57, 59, 123]. I Norway the cumulative HCV treatment uptake in OST patients 
during 2004-2013 was 14%, and the annual treatment rate <3% per year [136].
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3.9 DAA treatment studies in PWID
In a post-hoc analysis of OST patients in phase II/III trials, SVR rates were similar 
to the non-OST patients [138]. However, the high SVR rates reflect the fact that 
the OST patients in these trials were not actively using drugs (since that was an 
exclusion criteria). There is now emerging data on DAA treatment in PWID and 
in the OST population and a few clinical trials have been of great importance for 
encouraging HCV treatment in PWID since they did not exclude and even actively 
included participants with current (injection) drug use.
Table 2. DAA treatment of OST/PWID populations in clinical trials, population-based 
cohorts and reviews.
Table 2. DAA treatment of OST/PWID populaons in clinical trials, populaon-based 
cohorts and reviews. 
oPnoitalupoPstnapicitraPydutS sive UDS EOT ITT SVR PP SVR 
)%()%()%()%()n(
Clinical trials             
Co-star [139]  301 OST/PWUD >60% 
     ITG 91.5 95.5* 
     DTG 89.5 
SIMPLIFY [126] 103 OST/PWUD >70% 97.1 94.2 
PREVAIL** [140] 150 OST/PWUD 47% 93*** 
15TOD
96 
98 
     GROUP 48 93 
15UAT 89 
Populaon-based cohort             
Marcías J, et al 778 non-OST/PWID 95 97 
2019 [141] 177 OST 92 95 
673 PWID 89 95 
weiveR
Hajarizadeh B,  1408 PWID/non-IDU 97.5 87.7 
et al, 2019 [142] 2987 OST 97.4 90.7 
670 PWID 96.9 87.4 
UDS = Urine drug screen, ITT = intenon to treat, PP = per protocol, ITG =immediate-treatment group, DTG = 
Deferred-treatment group, *modified ITT, **treatment contained INF-based regimens in the beginning of 
the study period, *** n=136, DOT = directly observed treatment, GROUP = group treatment, TAU = 
treatment as usual 
UDS = Urine drug screen, ITT = intention to treat, PP = per protocol, ITG =immediate-treatment 
group, DTG = Deferred-treatment group, *modified ITT, **treatment contained INF-based 
regimens in the beginning of the study period, *** n=136, DOT = directly observed treatment, 
GROUP = group treatment, TAU = treatment as usual
In the clinical trials, drug use was continuous during treatment and was not 
associated with lower rates of SVR compared to those not using drugs [126, 
139, 140]. Overall there was a high adherence to treatment. However, in the 
PREVAIL study, adherence was significantly lower in the ‘treatment as usual’ 
group compared to the ‘directly observed group’ group [140]. Also, recent 
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stimulant injecting (amphetamines and cocaine) in the SIMPLIFY study was 
associated with non-adherence [143]. On the other hand, non-adherence was not 
associated with lower levels of SVR [140, 143]. 
In the population-based cohort [141], response rates were lower among PWID 
compared to non-drug users, and in the review study [142], older age was associ-
ated with higher SVR (OR 2.8, p=0.006) and lower proportions of lost to follow-
up (OR 0.45, p=0.034) compared to younger age. 
The overall lower SVR rates in these studies could be explained by individuals 
lost to follow-up in these populations. This has raised the question whether SVR 
is the best marker for cure among PWID, or rather, if cure could be synonymous 
with adherence and EOT, with a focus on follow-up for possible reinfections [144]. 
However, lost to follow-up has also been associated with more active PWID which 
suggests a higher risk of reinfection [145].
3.10 Reinfection post SVR
With scale-up of HCV treatment in PWID there will be reinfections among those 
with on-going injection risk behaviour. Previous studies on reinfection-rates 
after INF-based treatment range from 2-6/100 PY but there are so far only a few 
published studies on reinfection after DAA treatment, with a limited amount of 
follow-up time [35]. 
In a modelling study, persistent treatment rates above 80/1000 (8%) in PWID 
resulted in an initial increased number of reinfections that, however, decreased 
over time [10]. This was explained by the fact that reinfections will occur to a 
higher extent than previously as chronically infected, and thus non-susceptible 
pre-treatment, will become susceptible for HCV after treatment induced SVR. 
A persistent high treatment rate of > 8% will, however, curb the reinfection rate 
over time (fig. 7). Thus, reinfections will occur but retreatment needs to be given 
as a part of the HCV elimination strategy [146].
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Figure 7. The concept of increased HCV reinfections post SVR among people with con-
tinuous risk behaviour due to an increased pool of HCV susceptible, and the need of a 
continuous high (>8%) treatment rate to curb reinfections over time. Here, visualized 
with Australian data from 2015 [10].
A large population-based cohort study (n=4,114) in Canada followed HCV inci-
dence rates post SVR among former (≥3 years post SVR, n=1,793) and recent (<3 
years post SVR, n=875) PWID treated with DAA. Overall, 40 reinfections were 
identified during 2,767 PY at risk with the highest IR among recent PWID (3.1/100 
PY) compared to former PWID (1.4/100 PY) and non-PWID (0.3/100 PY) [147]. 
In a Norwegian cohort study (n=138), HCV treated (PEG-INF/RBV) participants 
were followed-up for reinfection and behavioural characteristics, with a 7 years 
median follow-up time after SVR. All reinfections were found among those with 
a continuous injection risk behaviour. During the follow-up, a total of 12 reinfec-
tions were found, corresponding to a reinfection proportion of 32% (12/37) and 
an incidence rate of 6/100 PY [148]. 
In a recent published study from an NSP in Scotland, participants were offered HCV 
treatment with PEG/RBV ± PI [149]. Among 94 individuals who started treatment, 
82% reached SVR indicating good compliance. However, at follow-up after 18 
months, there were 15/77 (19.5%) reinfections in this high-risk population, with 
the cumulative reinfection rate of 21.5/100 PY, with a 70 person-year follow-up 
time. After 18 months, 9/26 (34.6%) were reinfected among those under the age 
of 30 years, consistent with higher rates of risk behaviour and HCV incidence 
rates among younger PWID [149]. 
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The reinfection rate after SVR in OST participants in another recent multi-center 
study was 3.4/100 PY during the first 24-week follow-up (n=301) and 2.3/100 PY 
in those followed another 6-24 months after EOT (n=191). Taking into account the 
number of patients who spontaneously cleared the reinfection (3/10), the overall 
reinfection rate was only 1.6/100 PY [139, 150]. The low HCV reinfection rate 
post SVR in this study was possibly caused by a selection bias, since all included 
patients participated in OST programs which reduces the risk for reinfections per se.
3.11 The HCV care cascade
Even with universal access to HCV treatment, patients still need to be linked to 
care. As many studies have shown, there are many factors that might negatively 
affect the ‘HCV care cascade’ or the ‘retention cascade’, defined as retention 
in every step from diagnosis to reaching SVR [10, 151, 152]. Over time, from 
screening of anti-HCV, through confirmation with an HCV-RNA test, linkage to 
a specialist assessment, a follow-up visit for a fibrosis assessment and finally a 
possible treatment start - a great proportion of patient will be lost to follow-up, 
as shown in figure 8.
The HCV care cascade is a specific challenge in populations with concomitant 
 co-morbidities such as on-going drug use, psychiatric co-morbidities or lack 
of social stability. By treating people infected with HCV geographically closer 
to where they already are accessing services, aiming for a ‘one-stop-shop’, the 
treatment retention cascade will be improved [151, 152]. Hence, HCV treatment 
should be offered in settings such as dependency disorder clinics, OST clinics, 
prisons and at NSP. 
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Figure 8. The concept of the ‘HCV care cascade’ among PWID [153].
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4 PREVENTION OF HCV
4.1 Harm reduction
There is no universally accepted definition of harm reduction but in 2019 the 
organisation Harm Reduction International presented a revised definition [154]:
“Harm reduction is grounded in justice and human rights – it focuses on positive 
change and on working with people without judgement, coercion, discrimination, 
or requiring that they stop using drugs as a precondition of support” 
In the article ‘How the harm reduction movement contrast itself against punitive 
prohibition’, by Tammi et al., harm reduction is defined through four theses on 
how to view drug use and people who use drugs; 1) Drug use as such should be 
viewed neutrally, not moralistically, 2) A person who uses drugs is a sovereign 
citizen and member of a community, not a deviant individual or only an object 
of measures, 3) Drug policy should be based on practice and science, not on ide-
ologies and dogmatism, 4) Drug policy should respect human rights and support 
justice, not trample on them in the name of a ‘war on drugs’ or the goal of a drug-
free society [155].
Needle syringe programs (NSP) and opioid substitution treatment (OST) are exam-
ples of harm reduction interventions. A recent global review of the access to these 
services noted that only 79 countries in the world have implemented these two 
interventions for PWID and only four countries (Australia, Austria, Netherlands 
and Norway) were considered as having high levels of NSP and OST [8, 156]. In 
the WHO strategy for HCV elimination, a goal of >300 needle/syringes distributed 
per PWID per year is proposed for an effective prevention of HIV and hepatitis 
transmission [11]. With a suboptimal needle/syringe coverage there is a risk of 
continuous spread of HIV and hepatitis [157-160]. So far, the global distribution 
coverage target for needle/syringes and OST has not been reached since only 33 
needle/syringes have been distributed per PWID per year, and only 16 per 100 
PWID are on OST (fig. 9) [156].
Harm reduction co-exists with other interventions such as demand reduction (e.g. 
primary prevention to drug use, fighting poverty, inequalities and stigma and 
treatment for dependency disorders) and supply reduction (e.g. destroying drug 
corps, interrupting drug trafficking, and targeting on drug dealing syndicates). 
These combined strategies are well summed-up in the ‘four pillars drug strategy’ 
that was first implemented in Europe in the 1990s and is based on four principals; 
1) harm reduction, 2) prevention 3) treatment and 4) enforcement [161]. Lastly, 
there is no contradiction in the harmony between harm reduction and restrictive 
drug policies, as in e.g. Finland and Sweden [162].
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4.2 NSP/NEP
HCV and other BBVs may be transmitted through both the sharing of needle/
syringes and other drug paraphernalia [163-165]. Needle syringe programs (NSP) 
and needle exchange programs (NEP), are recommended harm reduction interven-
tions to reduce the spread of HIV and hepatitis among PWID [5-8]. Review-of-
reviews have concluded that there is evidence for NSP in reducing injection risk 
behaviour and transmission of HIV but insufficient data to support the effective-
ness of preventing HCV transmission [13, 14, 166]. On the other hand, there are 
studies indicating that NSP may prevent HCV transmission, in particular when 
combining NSP with OST [6, 7]. 
The first NEP in Sweden started in Lund in 1986, followed by Malmö in 1987. 
Due to political decisions, further implementation was cancelled until 2006 when a 
new law allowed new NEP to start up. Up until 2011, only three NEP were running 
in Sweden, all in Region Skåne, due to a continuous political resistance towards 
NEP. Between 2012 and 2015 another two NEP opened [167]. Stockholm NEP 
opened in 2013 and had within the first year enrolled 1,100 participants and was 
thus the largest NEP in Sweden. 
In 2015, The Public Health Agency of Sweden published a guideline for ‘health 
promotion and prevention work with hepatitis and HIV for PWID’ [54]. The 
guideline recommended implementation of low threshold units targeting PWID 
with several interventions, including NEP. As a result, another five NEP opened 
between 2016-2017. In 2017, a total of 3,400 participants were enrolled in Swedish 
NEP and by the end of 2018, 16 out of 21 Swedish counties/regions provided 
NEP with a total of 21 NEP [168]. The coverage of needles and syringes per NEP 
participant in 2018, in Sweden, was 254 and 165, respectively (data from the 
InfCare NSP register). 
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Figure 9. Global targets for the distribution of needle/syringes and opioid substitution 
therapy [156]. 
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The current Swedish NEP legislations require that participants are above the age 
of 18 years (previously 20 years), are registered with a personal Swedish identity 
number (and thus no anonymity), are considered ‘permanent residents’ in the 
county/region where the NEP is situated and comply with mandatory and repeated 
testing for HIV and hepatitis.
4.3 Change in injection risk behaviour (IRB) over time
Several studies, reviews and reviews of reviews have investigated the effect of 
NEP/NSP on injection risk behaviour (IRB), here defined as receptive sharing of 
needle/syringes or paraphernalia [13, 166]. The overall conclusion in two reviews 
of reviews was that there is evidence to suggest that NEP is effective in reducing 
IRB [13, 166]. However, due to the lack of ‘robust quality of evidence’ and pres-
ence of some biases, both reviews suggested the need for more data and future 
community-level studies to identify interventions needed to prevent transmission 
of BBVs [13, 166].
Table 3. Reviews and reviews of reviews addressing NEP/NSP effect on IRBTable 3. Reviews and reviews of reviews addressing NEP/NSP effect on IRB 
Study Type Year Studies (n) Conclusion 
Palmateer et al. [13] Review of reviews 2010   Sufficient data for NSP in reducing self-reported IRB.  
     Gibson et al  Review 2001 23      Clear statement of evidence for NSP effect on IRB 
     Woodak et al.  Review   2004 28      No clear statement for NSP and IRB 
     Tilson et al.  Review 2007 18      Clear statement of evidence for NSP effect on IRB 
Fernandes et al. [166]  Review of reviews 2017   NSP is ‘likely effecve’ in reducing IRB.  
     Cross et al.  Meta-analysis 1998 10      NSP associated with reduced IRB  
     Leonard et al. Review  1999 19      Support for NSP effect on reduced IRB 
     Gibson et al  Review  2001 23      Substanal evidence for NSP effect on reduced IRB 
     Tilson et al.  Review  2007 18      Moderate effect of NSP on reduced IRB 
     Jones et al.  Review  2008 7      Conflicng statement of NSP effect on IRB 
     Turner et al  Meta-analysis 2011 4      NSP associated with reduced IRB 
Some studies in the reviews investigating the effect of NEP on IRB had prospective 
cohort designs [169-182]. However, most of the participants in these studies had 
a previous experience of NEP at baseline and most studies recruited street-based 
PWID and compared change in IRB between those with access to NEP and those 
without access. In conclusion, most prospective studies reported a decline in IRB 
at follow-up, with a greater reduction among NEP users.
Four studies (one outside of the above mentioned reviews) which investigated the 
prospective prevalence of IRB exclusively within a NEP, were identified. Hart et 
al, noted a reduction of ‘sharing’ among participants (n=76) from 15% to 11% after 
three to four months follow-up [174]. Vlahov et al, noted significant reductions 
in self-reported use of previously used syringe (22% to 11%) among participants 
(n=221) after a six months follow-up [181]. Vertefeuille et al, noted significant 
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reductions of self-reported use of previously used syringe (23% to 11%), shar-
ing cooker (70% to 50%) and sharing cotton (59% to 39%) among HIV positive 
participants (n=112) after a six months follow-up [180]. Finally, Hou et al, noted 
a reduction of IRB (28% to 10%) among participants (n=610) that were followed 
annually for up to three years with the greatest risk reduction found between base-
line and the first follow-up [183].
4.4 OST 
OST, also called opioid agonist treatment (AOT) is the term for pharmacologi-
cal treatment of severe opioid use disorder. Opioids include heroin, morphine, 
opium and synthetic opioids such as oxycodone, tramadol and fentanyl. OST with 
methadone or buprenorphine reduces opiate cravings and drug seeking behaviour 
through the long acting effect and elimination half-life on the opioid receptor of 
these drugs (compared to the short duration of effect by e.g. heroin) [184]. The 
pharmacological treatment is often combined with psychosocial treatment to 
achieve better treatment outcomes [184]. OST can also comprise pharmacologi-
cal treatment of slow-release morphine or diacetyl-morphine (heroin) [185-188]. 
OST with methadone or buprenorphine is effective in treating opioid use disor-
der, protects against death by overdose and reduces the risk of transmission of 
blood borne viruses in particular when used in combination with NEP [189-191]. 
In 1966, as the second country in the world, Sweden implemented a methadone 
treatment program. However, due to governmental fear of over-use of methadone, 
only a limited number of patients were allowed to be included [192]. In 1999, with 
the introduction of buprenorphine, OST access was enhanced but overall access 
is still somewhat limited [124]. With updated Swedish guidelines in 2016, OST 
programs should aim to be more inclusive (with a lowered threshold for inclusion) 
and less excluding (decreasing involuntary discharges) [193]. The overall number 
of OST participants in Sweden has over the years gradually increased, with 4,468 
individuals having an OST prescription in 2017 and an estimated number of over 
5,000 in 2018 (personal communication Lars Håkan Nilsson) [167].
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5 TREATMENT AS PREVENTION
5.1 WHO elimination goals
In May 2016, The World Health Organization (WHO) presented a strategy to elimi-
nate hepatitis B and C as a global health threat by 2030, defined as a reduction of 
new infections by 90% and mortality by 65%, which would save approximately 
7.1 million lives [9]. A prerequisite for achieving this goal is to reach the ‘hard to 
reach’ population for diagnosis, treatment and prevention of reinfection. PWID 
are considered a part of the ‘hard to reach’ population, also in a Swedish context, 
and thus need to be targeted.
5.2 Mathematical modelling
Modelling studies aim to examine the possible effects of scaled-up HCV treat-
ment for the reduction of HCV in PWID. Other preventive measurements that 
could have an effect on prevalence may also be put into the model as combined 
interventions. Such combined interventions include high coverage of NSP and an 
increased access to OST, which altogether are the most effective combinations 
of interventions for HCV reduction [6, 191, 194, 195]. In order to model how the 
WHO’s goals can be achieved, several mathematical models have been developed. 
Although mathematical modelling may contain uncertainties in its forecasts, they 
give an indication of the level of intervention-inputs that may be required.
Figure 10. Modelling of HCV treatment of PWID. Baseline prevalence 25/50/65% [196]. 
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In 2013, Martin et al published a modelling-study on HCV elimination in PWID, 
which gained much attention [196]. The study modelled at what rate PWID must 
be treated to achieve a substantial reduction in the PWID HCV prevalence over 
time. With a baseline prevalence of 65% and a treatment rate of 80/1000 PWID per 
year (8%) over 15 years, the HCV prevalence would be reduced by 50% (fig. 10). 
In a Swedish context, with a high HCV background prevalence of around 60%, 
the model projects that an increase in treatment equivalent to 8% per year over 
15 years would reduce the HCV prevalence to around 30%. This corresponds to 
treatment of 960 PWID annually, assuming there are 12,000 chronically infected 
PWID in Sweden (Kåberg M, et al., unpublished).
A modelling-study from 2014 modelled the burden of HCV infection in Sweden 
and the impact of different DAA treatment strategies [50]. It was concluded that 
treating severe fibrosis (F3-F4) and doubling the annual treatment rate (to 2,260) 
would decrease HCC-incidence and liver-related deaths by 65–70% by 2030 but 
have no effect on overall prevalence and incidence. On the other hand, treating all 
(F0-F4) and doubling the annual treatment rate would have an effect on incidence 
and prevalence but less effect on liver related complications. 
A European PWID modelling-study estimated the rates of HCV treatment, NSP- and 
OST coverage and modelled different scenarios for decrease in HCV prevalence 
over a 10 years period (2016-2026) [197]. For Sweden, with an HCV baseline 
prevalence of 60%, doubling HCV treatment would have little effect on HCV 
prevalence but when treating 5% of the PWID population annually, the overall 
prevalence would decrease to 31.3% (25.1-38.0%) within 10 years. Furthermore, 
if HCV treatment scale-up was combined with a scale-up of NSP and OST cov-
erage to 80%, HCV prevalence would decrease to 9.9% (3.6-17.3%) over the 10 
years period [197].
5.3 Real world data
Real world data on HCV treatment and change in prevalence is now emerging. 
In Australia, universal access to HCV treatment is available since March 2016, 
including no treatment restriction regarding active drug use. On the contrary, the 
PWID population is a prioritized population in the Australian National Hepatitis 
C Strategy [198]. An Australian study examined treatment uptake and the viremic 
prevalence among PWID attending NSP nationally between 2015 and 2017 [199]. 
Within the sample population, treatment initiation increased from 10% in 2015 
to 41% in 2017 and the HCV viremic prevalence declined from 43% in 2015 to 
25% in 2017.
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5.3.1 HCV DAA treatment in Sweden
In Sweden, the number of treated patients has increased over time (fig. 11). During 
2018 the number of treated patients tripled after reimbursement restriction for 
treatment were lifted. However, these data do not specifically target PWID and 
the number of treatments within the PWID population in Sweden is still low.
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Figure 11. Number of HCV treated patients between 2014-2018. Data from the InfCare 
Hepatitis register.
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6 AIMS
The overall all aim of this thesis was to study different aspects of HCV infection 
among PWID at the Stockholm NEP.
6.1 Specific aims
1. To study the prevalence of HCV and pre-testing awareness of HCV status 
among PWID (paper I)
2. To study prevalence, incidence (rates), spontaneous clearance of HCV and 
associated baseline determinants in PWID (paper II)
3. To study HCV related liver fibrosis in PWID, using liver stiffness measure-
ment (LSM), APRI and FIB-4 score, and weather mild or advanced fibrosis 
was found and correlate this to age and duration of IDU (paper III)
4. To study differences in baseline characteristics and risk behaviour depending 
on time-point of admission in the program (paper IV).
5. To study change in injection risk behaviour over time among PWID 
(paper IV)
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7 MATERIAL AND METHODS
7.1 Patients, setting and study design
All studies were performed at the Stockholm NEP. The Stockholm NEP first opened 
in April 2013. In total 3,023 (fig. 12) were included in the Stockholm NEP during 
the first five years (2013-2018).
Paper III 
Hepas C virus (HCV) related 
liver fibrosis in people who inject 
drugs (PWID) at the Stockholm 
Needle Exchange – evaluated with 
liver elascity 
(n=203) 
Enrolled parcipants in the Stockholm Needle Exchange Program 
April 2013 to April 2018 (n=3023) 
Paper I 
Prevalence of hepas C and pre-
tesng awareness of hepas C
status in 1500 consecuve PWID
parcipants at the Stockholm 
needle exchange 
(n=1504) 
Paper II 
Incidence and spontaneous 
clearance of hepas C virus 
(HCV) in people who inject drugs
at the Stockholm Needle 
Exchange – Importance for HCV 
eliminaon 
(n=2320) 
Paper IV 
Long-term changes in injecon 
risk behaviours among 
parcipants in a needle exchange 
program 
(n=2860) 
Figure 12. Overview of the study population in study I-IV.
7.1.1 The Stockholm Needle Exchange
The Stockholm NEP offers exchange of injection equipment, i.e. needle/syringe 
and paraphernalia, and testing for hepatitis A (HAV), HBV, HCV and HIV at inclu-
sion is mandatory. General counselling, treatment for infectious diseases, referrals 
to social services and dependency disorder units including OST is provided. The 
NEP is organised by physicians and nurses specialised in infectious diseases and 
psychiatry/addiction medicine, a counsellor and midwives. 
Participants were registered with their unique Swedish personal identity number, 
while those without were provided with a unique reserve number. At first regis-
tration, all participants participated in a face-to-face interview performed by NEP 
staff containing 34 questions on baseline demographics (country of birth, level of 
education, marital status, housing conditions and employment), past and ongoing 
drug use, contacts with health care services, social services, prison and prohibi-
tion services. All participants also reported their own pre-test awareness of current 
HIV, HBV and/or HCV status. 
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Risk behaviour was measured through face-to face interviews at baseline and 
follow-up. The following definitions of self-reported injection risk behaviour 
were used: 1) Having shared needle/syringe for IDU with somebody during the 
past month (yes or no); 2) Having shared paraphernalia with somebody during 
the past month (yes or no). Questionnaires and tests for HIV and hepatitis were 
repeated at an interval of 3-6 months.
7.1.2 Study I
In this cross-sectional study, all 1504 individuals attending the Stockholm NEP 
between April 8th 2013 and October 16th 2014 were consecutively included to 
investigate overall HCV prevalence and pre-testing awareness of HCV status. 
Participants were interviewed to report their own pre-test awareness of current 
HCV status and to report age at first IDU. Following completion of the question-
naire, venipuncture was performed for BBV tests, including HCV. We further 
investigated the prevalence of anti-HCV in correlation to duration of IDU to esti-
mate the time to first HCV exposure among the NEP participants. The baseline 
characteristics of the included patients in the final analyses (n=1,386) are described 
in Table 1 of paper I.
7.1.3 Study II
In this prospective open cohort study we investigated HCV incidence, spontane-
ous HCV clearance, and determinants associated with new HCV infections and 
reinfections among the Stockholm NEP participants. All patients enrolled in the 
Stockholm NEP between 8th of April 2013 and 23rd of September 2016 (n=2,320) 
were tested for HCV at admission, and all responded to a questionnaire regarding 
sociodemographic data and injection risk behaviour. Follow-up tests for HCV were 
repeated at an interval of 3-6 months to prospectively identify new HCV infec-
tions (and reinfections) among those who were HCV susceptible (n=584). The 
baseline characteristics of the included patients in the final analyses are described 
in Table 1 of paper II.
7.1.4 Study III
In this open inclusion cross-sectional study we investigated HCV related liver 
fibrosis among NEP participant. Between December 8th 2016 and April 24th 2018 
all patients with chronic HCV infection (CHC) infection, defined as positive HCV 
RNA tests > 6 months (n=964), were offered evaluation of liver fibrosis on-site, 
including liver stiffness measurement (LSM), a medical history and expanded blood 
tests to evaluate APRI and FIB-4 scores. Furthermore, the participant demographics 
(i.e. age, duration of IDU), history of alcohol use, diabetes mellitus and body mass 
index were correlated to weather mild or advanced fibrosis, as defined by LSM 
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(cut-off 9.5 kPa), was found. The baseline characteristics of the included patients 
in the final analyses (n=203) are described in Table 1 and Table II of paper III.
7.1.5 Study IV
In this prospective cohort study we investigated injection risk behaviour, recep-
tive sharing of needle and/or syringe and paraphernalia (i.e. cookers and filters) at 
baseline and over a five-year follow-up (2013-2018) among the Stockholm NEP 
participant (n=2,860). Furthermore, we investigated demographic and drug-related 
determinants of risk behaviour. 
Risk behaviour was measured through interviews at baseline and follow-up. The 
first follow-up point was set at 6 months (±2 months) to identify possible early 
changes in risk behaviour following entry into the NEP. Thereafter follow-up time 
points were set at 12 months intervals from inclusion with a time span of ±3-5 
months to allow for individual variation resulting in the following follow-up regi-
men: 12 (±3 months), 24 (±5 months), 36 (±5 months) and lastly 48 (±5 months) 
months. Based on previous research [108, 200, 201], eleven baseline determinants 
were selected for inclusion in the statistical analysis. The baseline characteristics 
of the included patients in the final analyses are described in Table 1 of paper IV.
7.2 Methods
7.2.1 InfCare NSP (Needle Syringe Program)
The InfCare Needle Syringe Program database (InfCare NSP) is a clinical decision 
tool for collecting and analysing data for participants in the Stockholm NEP (fig. 
13). InfCare NSP was first introduced with the opening of the Stockholm NEP 
in 2013. Previously, there was no national consensus on collection and reports of 
data, apart from the mandatory annual report to the Swedish Board of Health and 
Welfare, later the Health and Social Care Inspectorate (IVO). 
In 2011, the Swedish Centre for Disease Control, later The Public Health Agency 
of Sweden, together with representatives from the Stockholm NEP and the Region 
Skåne NEP, met to decide on a battery of question that would be the base for future 
data collection and possible research. The questions decided on were a mix of the 
mandatory questions for reports to IVO and validated questions from the Australian 
National NSP Survey Reports, the European Centre for Disease Prevention and 
Control (ECDC), the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) and the United Nations Office on Drugs and Crime (UNODC). The 
questions reaching consensus, were implemented into InfCare NSP and are the 
base for demographic data and risk behaviour data used in the studies of this thesis.
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Figure 13. Graphic presentation of data in InfCare NSP. The blue and red lines depict 
the injection risk behaviour over time. The bars in the bottom display information on 
visit regularity, follow-up questionnaires (bars in black, red and purple), given vaccina-
tions (blue squares) and serological markers (red/green +/-)
7.2.2 Immunological methods
All serological tests for HIV, HBV and HCV were performed routinely using the 
Abbott Architect tests (HIV Ag/ab Combo, HBsAg Qualitative II, Anti-HBc II, 
Anti-HBs, Anti-HCV). 
7.2.3 Virological methods
HCV RNA was analysed in anti-HCV positive samples using Roche Diagnostics 
(Cobas TaqMan HCV Quantitative test and Cobas HCV, limit of detection 15 IU/ml).
7.2.4 Biochemical methods
All biochemical tests were performed at Karolinska University Laboratory using 
routine methods. A phosphatidylethanol test (B-PEth) is a specific alcohol marker 
in blood with high sensitivity [202, 203]. A result of < 0.05 μmol/l represents no 
or low/sporadic alcohol consumption, 0.05-0.30 μmol/l a moderate alcohol con-
sumption, and > 0.30 μmol/l a severe/continuous consumption [204].
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7.2.5 Assessment of liver fibrosis
Liver stiffness measurement
Liver stiffness measurement (LSM) was performed with transient elastography, a 
non-invasive assessment of liver fibrosis [64]. The result is obtained in kilo Pascal 
(kPa) and the value was correlated to the stage of liver fibrosis (Metavir F0-F4). 
Liver stiffness cut-offs in accordance with Swedish HCV treatment guidelines were 
< 7 kPa for Metavir F0-F1, 7-9.4 kPa for Metavir F2, 9.5-12.4 kPa for Metavir 
F3 and ≥ 12.5 kPa for Metavir F4 indicating cirrhosis [43, 67]. Individuals were 
further classified as having mild or advanced fibrosis. Mild fibrosis corresponded 
to LSM levels 9.4 or less and advanced to ≥ 9.5 kPa. The liver elasticity (LSM) 
was measured using FibroScan 402® with an M probe. Experienced members of 
the staff performed the LSM assessment. All participants were fasting for at least 
2 hours prior to assessment. A valid assessment was defined as ≥ 10 successful 
readings with a success rate of > 60% and an interquartile range of < 30%.
Fibrosis scores
APRI (AST to platelet ratio index) score was calculated as: AST (μkat/l) / [AST 
(upper limit normal, μkat/l)] x 100 / platelet count (109/L). An APRI score greater 
than 1.0 has a sensitivity of 77% and specificity of 75% for predicting F3-F4 [68].
FIB-4 (Fibrosis-4) score was calculated as: [Age (years) x AST (U/L)] / [platelet 
count (109/L) / √−ALT ]. A FIB-4 score < 1.45 has a negative predictive value of 90% 
for advanced fibrosis and a FIB-4 > 3.25 a 97% specificity and a 65% positive 
predictive value to identify advanced fibrosis [205].
ALT and AST upper limit of normal was 1.1 and 0.76 μkat/L and for men, and 
0.76 and 0.61 μkat/L, respectively for women. ALT and AST in μkat/L were nor-
malised to U/L for the FIB-4 score, where upper normal limit for was 35 U/L for 
ALT and 40 U/L for AST.
7.2.6 AUDIT-C
The AUDIT-C questionnaire is a short version of AUDIT (alcohol use disorder 
identification test) comprising three questions about alcohol consumption  patterns 
during the last year. The responses are summed up to a total score that varies 
between 0 and 12. As a cut-off score for risk use, 4 points were used for women 
and 5 points for men [206].
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7.2.7 Statistical methods
Data from InfCare NSP were exported to and analysed in the statistical programs, 
JMP 10.0-13.0 ® SAS Institute Inc. or STATA 15. 
All baseline demographic data were presented as proportions, mean or median 
levels with ranges. The Chi square test or Fisher exact two-tailed test was used to 
test categorical variables and the Wilcoxon rank sum test for continuous values. 
A p value <0.05 was considered statistically significant.
In paper II, a new HCV infection was defined as a negative HCV test (anti-HCV 
negative or HCV RNA negative test) at baseline followed by a later positive HCV 
test (anti-HCV or HCV-RNA positive). The actuarial method was used to define 
the time to HCV infection as the midpoint between the last HCV negative test 
and the following positive HCV test. All HCV susceptible subjects were followed 
over time to detect new HCV infections (or reinfections) or until the last follow-up 
test. Incidence rates (IR) were defined as number of new infections or reinfections 
(n=x) per 100 person-years (x/100 PY). 
In paper IV, the odds of the two of risk behaviours at baseline and five follow-up 
points, given the 11 determinants, were modelled using Generalized Estimating 
Equation (GEE) regression models [207]. Given the longitudinal nature of the 
data, GEE regression models were used to account for the potential dependence 
in the risk behaviours within participants over time. 
Associations between the single determinants and the odds of the risk behaviours 
at baseline were reported (Table 2 of paper IV) as well as relative change in odds 
of the risk behaviours over the five follow-up points for all determinant categories, 
together with a p-value testing for an overall change over time (Supplementary 
Table 1 of paper IV). Results were reported as odds ratios (ORs) with corresponding 
95% confidence intervals (CIs). All reported p-values was two-sided and p-values 
<0.05 was considered as statistically significant.
7.2.8 Ethics
All studies were performed in accordance to the Helsinki declaration and was 
approved by The Regional Ethical Review Board in Stockholm, file number; 
2013/495-31/3, 2015/1374-32 (study I-IV) and 2018/904-32 (study III).
Ethical considerations
In our studies, there were no considered physical risks in answering questionnaires, 
undergoing LSM examination or in data retrieval. Blood sampling, which involves 
puncture of the skin, may be experienced as physically unpleasant. To prevent 
and/or reduce physical discomfort, all samplings were carried out by trained and 
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experienced medical staff and there were no additional blood samplings outside 
of general clinical work. For every eventual undesired event there was a plan for 
investigation, report and documentation in accordance with routines within Region 
Stockholm Healthcare (SLL).
No particular benefit comes from participation in study I, II and IV, beside the 
regular preventive activities for the individual. A needle exchange program con-
tributes to benefits for the participants and PWID in terms of general prevention 
of blood borne diseases. Thus, we did not identify disadvantages of these studies 
for the group as a whole.
In study III, involving liver stiffness measurement with Fibroscan®, participants 
gained increased knowledge about their current medical situation and level of liver 
fibrosis and were also offered HCV treatment on-site or referral for treatment in 
accordance to Swedish HCV treatment guidelines. Studying HCV related liver 
health at the Stockholm NEP have thus contributed to benefits for the participants 
in the form of increased knowledge of liver health and HCV treatment that may 
reduce liver related morbidity and mortality. 
Individuals attending the Stockholm NEP are in active drug use and may be under 
the influence of or intoxicated by illicit drugs. This had to be taken into account 
in the interaction with the participants, in the general health care provision, when 
performing research studies and in the interpretation of the results in this population. 
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8 RESULTS AND DISCUSSION
8.1 Prevalence of HCV and pre-testing awareness of 
HCV status (study I)
Among the participants in the final analyses (n=1,386) the anti-HCV prevalence 
was 82%, whereof 75% were HCV RNA positive verifying a viremic HCV infec-
tion. Hence, the prevalence of a viremic HCV infection in PWID in this Stockholm 
cohort was 62%. However, as more participants were enrolled in the Stockholm 
NEP, more participants were included in the studies which had an effect on overall 
HCV prevalence as depicted in table 4.
Table 4. Change in overall HCV prevalence with more included participants in 
study I-IV.
Table 4. Change in overall HCV prevalence with more included par	cipants in study I-IV. 
Par	cipants Year an	-HCV HCV-RNA 
  (n)   prevalence (%) prevalence (%) 
Study I  1386 2013-2014 82.2 62.1 
Study II  2320 2013-2016 77.2  57.4 
Study III  2037 2016-2018 76.1 56.9 
Study IV  2860 2013-2018 73.7 55.0 
The very high prevalence of anti-HCV, found among the 1,386 participants, was 
higher compared to many other major cities worldwide, for example Edinburgh in 
Scotland and Melbourne in Australia, but of the same magnitude as that reported 
from Vancouver, Canada [196].
Among the participants who reported a chronic HCV infection 99% were anti-
HCV positive reflecting either a chronic HCV infection or a spontaneously cleared 
infection (Table 3 in paper I). However, 14% of those who believed that they had 
a chronic HCV infection were in fact HCV RNA negative (Table 4 in paper I). 
Furthermore, among those who believed that they never had encountered HCV 32% 
were anti-HCV positive and 24% HCV RNA positive. Of the 138 individuals who 
stated that they had spontaneously cleared their HCV infection, 32% were HCV 
RNA positive indicating a chronic HCV infection. Finally, of the 40 participants 
who reported having received treatment for HCV, with the notion that they had 
cleared their infection, 33 % were HCV RNA positive. 
One important factor for effective harm reduction, and linkage to care, is HCV 
awareness among PWID on an individual level. The result of the present study 
showed that this awareness was lacking in large segments of PWID and that the 
self-reported HCV status differed from the actual status in many cases. Thus, 
participants who were not aware of being HCV infected carried an increased risk 
to transmit HCV to other PWID, and those who believed that they already were 
infected (but were not) had increased risk behaviour that may result in reinfections. 
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The participants who self-reported “not having” HCV infection had a significantly 
reduced injection risk behaviour compared to those reported “having” HCV. 
Thus, 22% of those who reported “not having” HCV reported sharing needles and 
syringes the past month compared to 35% of those who reported “having HCV”, 
(p < 0.0001). The corresponding figures for PWID sharing paraphernalia during 
the past month were 27% and 41% respectively, (p < 0.0001).
The overall limited HCV awareness indicates a need for repeated HCV testing 
with reflex testing (automatic analysis of HCV RNA among anti-HCV positive) as 
it is essential to diagnose and report back an accurate HCV status to better affect 
change in risk behaviour and for further linkage to care [208, 209]. 
Furthermore, we investigated the cumulated anti-HCV prevalence correlated to 
duration of IDU (fig. 3 in paper I). Over all, 50% had become anti-HCV positive 
after 4 years of IDU, women already after 2.3 years, and men after 4.9 years. The 
prevalence of anti-HCV in participants with IDU duration ≥10 years was 90%. 
This altogether indicate that prevention and harm reduction measures need to be 
implemented early on, at the very start of injection risk behaviour or if possible 
before injection use is started.
8.2 Change in injection risk behaviour over time among 
PWID (study IV)
At inclusion, 29% of the 2,860 participants in study IV had shared needle/syringe 
and 34% had shared paraphernalia during the past month, and one in five had 
engaged in both risk behaviours. The majority (60%), reported use of non-sterile 
equipment at last injection not necessarily representing receptive sharing, but indi-
cating re-use of their own needle/syringe. The prevalence of HIV, viremic HCV 
and HBV (HBsAg positive) were 4.9%, 55% and 1.4%, respectively
At inclusion, almost half of all women had shared needle/syringe (43%) and para-
phernalia (50%) during the past month compared to 25% vs. 29% for men (Table 
1 in paper IV). When adjusting for confounders (Table 2 in paper IV), women 
were twice as likely to share needle/syringe (OR 1.95, 95% CI 1.61; 2.35) and 
paraphernalia (OR 2.41, 95% CI 1.99; 2.91) compared to men.
Homeless participants reported higher risk for sharing both needle/syringe and 
paraphernalia compared to those with stable housing (OR 1.48, 95% CI 1.20; 1.82 
vs. OR 1.50, 95% CI 1.23; 1.83). At inclusion, participants ≥34 years of age had a 
35% lower risk for sharing needle/syringe compared to their younger peers (OR 
0.65, CI 95% 0.53; 0.80) (Table 2 in paper IV).
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Participants injecting amphetamine were 33% and 58% more likely to share needle/
syringe (OR 1.33, 95% CI 1.09; 1.61) and paraphernalia (OR 1.58, 95% CI 1.31; 
1.91) respectively, compared to participants injecting heroin. Being enrolled in 
OST was associated with significant lower levels of sharing needle/syringe (OR 
0.66, CI 95% 0.46; 0.95) and sharing paraphernalia (OR 0.35, CI 95% 0.23; 0.51). 
At inclusion, HIV positive participants reported lower risk behaviour compared 
to HIV negative participants; needle/syringe (OR 0.56, CI 95% 0.35; 0.92) and 
paraphernalia (OR 0.62, CI 95% 0.40; 0.96). However, HCV positive participants 
reported higher levels of risk behaviour; needle/syringe (OR 1.31, CI 95% 1.10; 
1.58) and paraphernalia (OR 1.41, CI 95% 1.18; 1.68) (Table 2 in paper IV).
8.2.1 Change in risk behaviour over time in the NEP 
In figure 14, the change in risk behaviour in participants at different time-points 
following inclusion in the NEP is displayed.
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Figure 14. Change in injection risk behaviour (sharing needle/syringe and parapher-
nalia) following inclusion in the NEP. Odds ratio (OR) at inclusion is set at 1 as refer-
ence value. N=2860 at inclusion. P-values represent changes in risk behaviour over the 
whole time period.
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Over all, there was a decrease in injection risk behaviour over time, both in shar-
ing of needle/syringe and paraphernalia (p<0.0001 and p<0.0001), with reductions 
seen already after 6 months. There were significant decreases in risk behaviour 
over time by gender, living situation, heroin and amphetamine use, age at IDU 
debut and duration of IDU. However, those enrolled in OST, who were HIV-
positive or younger (< 24 years at inclusion) did not decrease their risk behaviour 
(Supplementary Table 1 in paper IV).  
We thus found a risk reduction in women already after 6 months regarding shar-
ing of paraphernalia which became evident in men only after 12 months. Even 
though both women and men reduced risk behaviour over time, women consistently 
reported higher risk levels than men at each time-point (Supplementary Table 2 
in paper IV). This rapid change in risk behaviour, already within the first year, is 
consistent with data from a longitudinal study from Baltimore, USA, where the 
greatest risk reduction was noticed within the first-year of follow-up [183].
8.2.2 Baseline determinants and risk behaviour by year of inclu-
sion in the NEP
Participants enrolled in the NEP year five (of the study period) were younger, 
reported later IDU debut and shorter duration of IDU compared to individuals 
enrolled at year one. Furthermore, the prevalence of HCV declined from 61% to 
42%, p<0.001. There were, however, no major differences in proportions of baseline 
injection risk behaviour for the different years of inclusion. (Table 3 in paper IV). 
In summary, our findings confirmed and highlighted that women were twice as 
likely as men to share needle/syringe as well as paraphernalia, as found in other 
studies [210-212]. Furthermore, PWID with stable housing conditions reported 
lower levels of injection risk behaviour compared to homeless [108, 213, 214]. We 
also noted that an early drug and injection debut was associated with a high risk 
behaviour level [108, 211, 215]. Those injecting amphetamine were more likely 
to share injection equipment compared to those who were injecting heroin. Being 
enrolled in OST however, was associated with lower risk behaviour, as shown in 
previous reviews [5, 7, 191].
As expected, HCV-positive PWID also reported higher risk behaviour at baseline 
compared to those uninfected. The reverse relationship found among HIV posi-
tive participants, where an HIV positive status was associated with lower risk 
behaviour, may be explained by changes in risk behaviour in PWID after being 
diagnosed with HIV and/or possibly also by the required mandatory contact with 
HIV health care.
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8.3 Incidence and spontaneous clearance of HCV and 
associated demographic factors (study II)
In study II, all HCV susceptible subjects (n=584) were followed until seroconver-
sion or reinfection occurred, or to the time point for the last negative HCV test. 
The overall HCV incidence rate was 22/100 PY. The HCV incidence rate in the 
HCV naive (anti-HCV negative) group was 26/100 PY and in the spontaneously 
cleared (HCV RNA negative) group 19/100 PY. Although there were no significant 
differences in becoming HCV infected between the two groups (31% vs. 29%), 
the rate of spontaneous HCV clearance was significantly lower in the HCV naive 
group 20% compared to the spontaneously cleared (and thus previously HCV 
experienced) group 44%, (p <0.05).
During follow-up in the HCV naive group, 31% became HCV infected. Baseline 
factors associated with HCV infection were female gender, younger age, short 
duration of IDU, homelessness, low education level and sharing needle/syringe 
the past month. In participants with a spontaneously cleared HCV infection, 29% 
were reinfected during follow-up. Here, baseline factors associated with reinfection 
were younger age, shorter duration of IDU and homelessness. Incidence rates in the 
spontaneously cleared cohort were in general lower than in the HCV naive group. 
Despite the significant decrease in injection risk behaviour as noted in study IV, 
the HCV incidence rates were high and in line with previous findings in many 
countries [2, 35, 96-98]. 
Real world data on HCV incidence and reinfections rates among PWID in high 
prevalence settings is needed. Such data was provided in our study, with a pooled 
HCV incidence rate of 22/100 PY in the Stockholm PWID cohort. This may reflect 
the possible future levels of reinfection rates, when DAA treatment will be scaled 
up in Stockholm. There is however no evidence that HCV incidence outside HCV 
treatment and after SVR necessarily mirrors each other. On the contrary, these 
rates seem to diminish after SVR has been achieved [216, 217] although a recently 
published HCV treatment and reinfection study, in an NSP setting in Scotland, 
noted a reinfection rate of 21.5/100 PY [149].
A high reinfection rate post SVR poses a great challenge, and if HCV treatment 
per se will reduce the injecting risk behaviour or not needs to be studied further. 
One study indicates a reduced risk behaviour during treatment and post SVR, in 
spite of no significant change in daily injecting habits [216].
The high HCV incidence rate in the Stockholm PWID cohort highlights the need 
for interventions among NEP participants. Since the start of the NEP in 2013, 
3,300 PWID have been enrolled and 1,800 unique PWID attended the program 
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in 2018. Data from 2018 showed that the mean needle and syringe coverage rate 
for NEP participants in Stockholm was 220 and 180 per person/year, respectively 
and thus below the recommended number in WHO guidelines of 300 needle/
syringes per PWID per year, needed to reach an adequate prevention of blood 
borne viruses [11, 218]. 
The results in study II and IV further highlights the need for combined interven-
tions, such as high coverage NEP, scale-up of HCV treatment and provision of 
OST, for effective HCV prevention, as concluded in previous studies [6, 13, 15]. 
In a recent Cochrane report, Platt et al. concluded that OST was associated with a 
50% reduction in the HCV transmission rate, and that NEP alone was less effec-
tive with only a 21% reduction of the transmission rate. When stratified by region, 
a 56% risk reduction was found in settings with high coverage NEP in Europe. 
Combined OST/NEP on the other hand was associated with a 74% reduction of 
the HCV transmission rate [7].
8.4 Evaluation of HCV related liver fibrosis using liver 
stiffness measurement (LSM), APRI and FIB-4 score 
(study III)
A total of 203 participants were evaluated with liver stiffness measurement (LSM) 
which was used for fibrosis evaluation. The overall mean value was 7.2 kPa indi-
cating that a majority had mild fibrosis. Among evaluated participants, 9% had F3 
(9.5-12.4 kPa) and 6% F4 (≥ 12.5 kPa) indicating advanced fibrosis in only 15%.
Overall, a third (34%) reported having a risk consumption of alcohol during the 
past year by AUDIT-C. There was no significant correlation between alcohol 
consumption (self-reported risk consumption, PEth > 0.05, PEth > 0.3, or previ-
ous treatment for alcohol use disorder) and fibrosis stage (mild versus advanced). 
Furthermore, we found no significant association between diabetes mellitus or 
body mass index ≥ 30 and fibrosis stage (mild versus advanced).
However, our data may have failed to identify the risk use of alcohol over a longer 
duration of time. Defining long-term risk use of alcohol in our PWID population 
is a challenge and we might have failed to do this properly. Self-reported data 
on ever having treatment for alcohol use disorder may also be response biased. 
Furthermore, a high percentage of individuals with alcohol use disorders never 
seek treatment [219, 220]. It is well known that any level of alcohol consumption 
in combination with HCV infection, constitute a health risk [221, 222]. 
Only 3% had diabetes and 7% a BMI ≥30, respectively. Consequently, the influ-
ence of diabetes and BMI on advanced fibrosis could not be properly evaluated.
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A total of 12% participants had an APRI score > 1. The APRI score was signifi-
cantly correlated to fibrosis stages and differed in participants with mild versus 
advanced fibrosis (p<0.0001) and in participants with or without cirrhosis (LSM 
≥ 12.5 versus LSM ≤ 12.4). Only 9/23 (39%) of participants with APRI > 1 had 
advanced fibrosis (LSM ≥ 9.5) and conversely an APRI score > 1 identified only 
9/30 (30.0%) of all participants with advanced fibrosis. 
We also noted an overall significant difference in FIB-4 cut-off (1.45 < and >3.25) 
and mild versus advanced fibrosis (p<0.001). However, only 9/30 (30%) of par-
ticipants with advanced fibrosis had a FIB-4 level > 3.25. Taken together, when 
using an APRI score >1 or a FIB-4 level >3.25 as cut-offs for finding participants 
with advanced fibrosis (LSM ≥ 9.5 kPa), only a limited part of those with advanced 
fibrosis was identified.
8.4.1 Use of age and IDU duration to detect advanced fibrosis
Of all participants, 56% were both aged ≥ 40 years and had an IDU duration ≥ 15 
years. Participants aged ≥ 40 years or with an IDU duration ≥ 15 were significantly 
more likely to have advanced fibrosis (p<0.001 and p<0.01). With these respective 
cut-offs, 28/31 (90%) participants with advanced fibroses were identified (Table 
2 in paper III). 
An age of ≥ 40 years in combination with an IDU duration of ≥ 15 years identi-
fied 26/31 (84%) of participants with advanced fibrosis, however only 26/114 
(23%) actually had advanced fibrosis with this cut-off. APRI > 1 was present in 
13/23 (57%) of participants with an age of ≥ 40 years and an IDU duration of 
≥ 15 years. When an APRI score of > 1 was combined with age ≥ 40 years in 
combination with an IDU duration of ≥ 15 years, all 31(100%) participants with 
advanced fibrosis were detected. The overlap of age of ≥ 40 years, IDU duration 
of ≥ 15 and APRI > 1 is displayed in a Venn diagram (fig. 15).
In summary, we found that only 15% of PWID in the Stockholm NEP had advanced 
fibrosis (LSM ≥ 9.5 kPa) roughly corresponding to Metavir fibrosis stage F3 and 
F4. Those with advanced fibrosis are in need of immediate treatment for HCV to 
prevent further disease progression and also need to be included in HCC screening 
programs. Assessment with LSM has been well received in PWID and is reason-
ably effective in identifying advanced fibrosis [125, 223]. Treatment guidelines 
also recommend that fibrosis severity must be assessed, since it may predict future 
liver-related events [83, 224]. 
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With universal access to HCV treatment, without fibrosis restriction, the need for 
LSM evaluation has diminished. Previously, LSM was used to distinguish those 
eligible for HCV treatment (with fibrosis stage ≥ F2). However, LSM evaluation to 
exclude or confirm severe fibrosis is still of great importance. A mandatory LSM 
assessment pre-treatment, however, may be a limiting factor and will thus have a 
negative impact on the efficacy of the HCV care cascade [10]. 
In our study we found that the diagnostic work-up for advanced fibrosis can be 
simplified with a combination of easily available factors such as age, duration of 
IDU and an APRI score. This allows identification of PWID in need of immediate 
HCV treatment to prevent further disease progression and furthermore, LSM can 
be avoided among PWID with mild fibrosis, identified by age <40 years com-
bined with IDU duration of <15 years and APRI score <1. This strategy enhances 
the HCV care cascade where LSM is not easily available, and will thus facilitate 
HCV treatment initiation
8.5 Strengths and limitations
Several limitations must be considered when interpreting the results of these 
 studies. Much of the data in all four studies (I-IV) relies on self-reported data from 
the participants at the Stockholm NEP. Given the nature of data collection from 
Age ≥ 40: n=132
Age ≥ 40 and LSM ≥ 9.5 kPa: n=28
IDU ≥ 15: n=137
IDU ≥ 15 and LSM ≥ 9.5 kPa: n=28
APRI > 1: n=23
APRI > 1 and LSM ≥ 9.5 kPa: n=9
1
1
1
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Figure 15. Venn diagram of overlap between age ≥ 40, duration of injection drug use 
(IDU) ≥ 15 years, APRI score > 1 and advanced fibrosis, ≥ 9.5 kPa (filled purple circle).
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face-to-face interviews, there is a risk for recall-bias as well as social desirability 
bias (e.g. under-reporting of risk behaviour).
Following a large cohort over time may also lead to attrition bias. We have had 
no opportunity to follow participants outside of the NEP and participants may 
have been lost to follow-up due to a variety of reasons not known to us, including 
voluntary termination from the NEP (e.g. choose not to come back or no longer 
being PWID), incarceration, geographically moving from the service and death 
(although the vast majorities of deaths are automatically registered in our charts). 
In study II we used the actuarial method to calculate the time interval to the infec-
tion or reinfection, this might have underestimated the actual time interval. We 
reasoned however, that the actuarial time used, was more reasonable since the 
actual time for seroconversion and reinfection was unknown due to long intervals 
used between blood sampling.
In study I-IV we defined duration of IDU as the difference between current age 
and self-reported age of injection drug debut. In this estimate we have not taken 
into account the possibility of long periods of abstinence from IDU. Furthermore, 
the debut of IDU is not necessarily concurrent with being HCV exposed, although 
our previous data have generally demonstrated early acquisition of HCV infec-
tion [200, 201]. 
In study III we used LSM as the method to detect advanced fibrosis. However, LSM 
may be subject to confounding factors such as acute/unspecific liver inflammation, 
congestive heart failure, liver blood congestion after a meal, and obesity, which 
all are factors that can interfere and cause false high LSM levels. To minimize 
confounders when utilizing LSM, our participants were investigated in a fasting 
state, were evaluated for alcohol use and were subjected to expanded blood tests. 
Lastly, in Sweden the legislation surrounding NEP requires participants to provide 
identification documents before admission into a NEP. Also, entry to a Swedish 
NEP requires an age ≥ 18 (previously 20 years) and mandatory testing for HIV 
and hepatitis. These procedures may have deterred some PWID from participa-
tion. On the other hand, these requirements did provide the opportunity to collect 
prospective clinical program data on an individual level.
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9 CONCLUSION
In the four studies, performed at the Stockholm NEP between 2013-2018 we found: 
• A high 60% baseline prevalence of HCV was noted at entry in the program 
which tended to decrease with more participants enrolled in the program, 
mainly explained by the enrollment of younger not yet HCV infected partici-
pants over time. 
• A low awareness of the actual HCV status among PWID at enrollment was 
noted which will have influence on injection risk behaviour in PWID and 
will increase the risk of HCV transmission.
• That female gender, homelessness and amphetamine use were baseline 
determinants correlated to sharing needle/syringes and paraphernalia, 
whereas OST was a protective factor.
• That there was an overall significant reduction in injection risk behaviour of 
most baseline risk factors over time in the Stockholm NEP. 
• That PWID in Stockholm became HCV infected relatively early. Thus 50% 
became anti-HCV positive within 2-5 years after debut of IDU.
• That despite a significant reduction in injection risk behaviour over time, a 
high HCV incidence rate was still noted both among those who were HCV 
naive (26/100 PY) and those who had spontaneously cleared the HCV infec-
tion (19/100 PY). 
• That female gender, homelessness and amphetamine use at baseline was 
correlated to a new HCV infection, the same baseline determinants as noted 
for injection risk behaviour. 
• That advanced HCV related liver fibrosis was seen in only 15% of PWID in 
the NEP, making them prioritized for HCV treatment and HCC surveillance.
• That a combined use of age ≥40 and IDU duration ≥15 years in combination 
with APRI score > 1could be used to pinpoint PWID with advanced fibrosis.
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10 SAMMANFATTNING PÅ SVENSKA
Den främsta orsaken till att hepatit C-virus sprids är att personer som injicerar droger 
delar icke-steril injektionsutrustning, d.v.s. nålar, sprutor och andra injektions-
tillbehör (droglösning, uppdragningskärl och filter). Sprututbytesprogram bidrar 
till minskat injektionsriskbeteende och minskad spridning av hepatit C hos per-
soner som injicerar droger. Världshälsoorganisationen (WHO) har satt upp ett mål 
att eliminera hepatit C till år 2030. För att uppnå det målet behövs ökad kunskap 
kring förekomst och spridning av hepatit C i den grupp som är mest utsatt för risk. 
Syftet med avhandlingen var därför att studera förekomst av hepatit C, frekvens 
av nysmitta, hur många som läker ut hepatit C, graden av leverskada orsakad av 
hepatit C samt hur förändring av injektionsriskbeteende ser ut över tid hos personer 
som injicerar droger och som är inskrivna på sprututbytet i Stockholm.
I första studien fann vi en hög (60%) förekomst av hepatit C-infektion samt att 
hälften (50%) blivit infekterade inom två till fem år efter injektionsdebut. Dessutom 
var medvetenheten begränsad kring huruvida man var infekterad av hepatit C eller 
inte i samband med det första besöket på sprututbytet. Dessa faktorer påverkar 
injektionsriskbeteendet och risken för spridning av hepatit C. Våra resultat indikerar 
att förebyggande åtgärder och skadereducerande insatser som sprututbyte måste 
tillgängliggöras i ett tidigt skede för att minska spridningen av hepatit C. 
I andra studien undersökte vi förekomst av nysmitta av hepatit C bland deltagarna 
på sprututbytet. Sammantaget noterades en hög grad av nysmitta som motsvarade 
22% per år. De som befann sig i ökad risk för att bli infekterade av hepatit C var 
kvinnor, hemlösa samt de som injicerade amfetamin. Personer som tidigare hade 
läkt ut sin hepatit C hade en större chans att göra det igen, jämfört med de som 
blev infekterade för första gången. Avgörande insatser för att minska spridningen 
av hepatit C är en kombination av 1) ökad tillgänglighet till sprututbytesverksam-
het, 2) behandling av hepatit C i gruppen som injicerar droger samt 3) tillgänglig 
och effektiv beroendevård som t.ex. läkemedelsassisterad rehabilitering vid opi-
oidberoende (LARO). 
I tredje studien undersökte vi graden av hepatit C-relaterad leverskada hos besökare 
på sprututbytet med hjälp ultraljud (Fibroscan). Vi noterade att 15% hade en 
avancerad fibros (ärrbildning i levern) och var därmed i behov av prioriterad 
behandling och fortsatt uppföljning för att minska risken för ytterligare lever-
skada. En ålder på över 40 år och en tid längre än 15 år sedan injektionsdebut 
var faktorer som ökade riken för att ha avancerad fibros. Våra resultat indikerar 
också att yngre personer med kortare tid sedan injektionsdebut kan behandlas 
utan föregående ultraljudsundersökning, vilket kan underlätta utredning och öka 
tillgängligheten till behandling. 
47
I fjärde studien noterade vi en signifikant minskning av injektionsriskbeteendet 
över tid hos deltagarna på sprututbytet. Kvinnor, hemlösa och de som injicerade 
amfetamin visade sig ha en ökad risk att dela nålar, sprutor och andra injektion-
stillbehör, medan LARO-behandling var en skyddande faktor. Över tid har spru-
tutbytet nått ett större antal individer som inte redan är infekterade av hepatit C 
i samband med första besöket, vilket skapar möjlighet att förebygga hepatit C i 
ett tidigare skede. 
Sammanfattningsvis har våra studier bidragit till en ökad kunskap om förekomsten 
och graden av nysmitta av hepatit C hos personer som injicerar droger. Våra resultat 
har också visat att deltagande i sprututbytesverksamhet leder till ett minskat injek-
tionsriskbeteende. Behovet av effektiva skadereducerande insatser för att förhindra 
spridningen av hepatit C är av stor betydelse. För att eliminera hepatit C till år 
2030, som WHO föreslagit, behövs ytterligare implementering av sprututbytes-
verksamhet i kombination med en ökad behandling av hepatit C bland personer 
som injicerar droger, samt en ökad tillgänglighet till effektiv  beroendebehandling 
som t.ex. LARO-verksamhet.
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